After another successful year serving our patients in Russia we enter 2020 geared up to comply with significant changes to changes in the Russian regulatory landscape. Our therapeutic area, hemophilia, is one of the first selected to implement product serialization and we are now supplying products with unique identifiers. In addition, we are facilitating the new law regarding local QP release in the Russian market. We look forward to continued success in this important treatment area.